Association of Serum Erythropoietin with Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study

Circulation: Heart Failure

Volumn 9, Issue 1, 2016, Pages

  Garimella, Pranav S ^a   Katz, Ronit ^b   Patel, Kushang V ^b   Kritchevsky, Stephen B ^c   Parikh, Chirag R ^d   Ix, Joachim H ^e   Fried, Linda F ^f   Newman, Anne B ^g   Shlipak, Michael G ^f,h   Harris, Tamara B ⁱ   Sarnak, Mark J ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Cardiovascular outcomes chronic kidney disease death erythropoietin heart failure

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; EPO PROTEIN, HUMAN;

AGED; ANEMIA; ARTICLE; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DETERIORATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; AGE; AGING; BLOOD; CLINICAL TRIAL; INCIDENCE; KAPLAN MEIER METHOD; KIDNEY; LONGITUDINAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; UNITED STATES; UPREGULATION;

AGE FACTORS; AGED; AGING; BIOMARKERS; BODY COMPOSITION; ERYTHROPOIETIN; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; UNITED STATES; UP-REGULATION;

EID: 84955243518     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.115.002124     Document Type: Article

References (44)

1. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818-827. doi: 10.1016/j.jacc.2008.04.061.
2. Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, Levey AS, Sarnak MJ. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005;16:3403-3410. doi: 10.1681/ASN.2005030226.
3. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631-1634. doi: 10.1681/ASN.2011111078.
4. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011;8:485-493. doi: 10.1038/nrcardio.2011.77.
5. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004;65:757-767. doi: 10.1111/j.1523-1755.2004.00450.x.
6. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098. doi: 10.1056/NEJMoa065485.
7. Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, Diamantidis CJ, Fink JC. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int. 2011;80:288-294. doi: 10.1038/ki.2011.49.
8. Druëke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084. doi: 10.1056/NEJMoa062276.
9. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368:1210-1219. doi: 10.1056/NEJMoa1214865.
10. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P; Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526-535. doi: 10.1161/CIRCULATIONAHA.107.698514.
11. George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T, Sheps D, Keren G. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med. 2005;165:1304-1309. doi: 10.1001/archinte.165.11.1304.
12. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol. 2004;44:63-67. doi: 10.1016/j.jacc.2004.03.052.
13. den Elzen WP, Willems JM, Westendorp RG, de Craen AJ, Blauw GJ, Ferrucci L, Assendelft WJ, Gussekloo J. Effect of erythropoietin levels on mortality in old age: the Leiden 85-plus Study. CMAJ. 2010;182:1953-1958. doi: 10.1503/cmaj.100374.
14. Wagner M, Alam A, Zimmermann J, Rauh K, Koljaja-Batzner A, Raff U, Wanner C, Schramm L. Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:1573-1579. doi: 10.2215/CJN.00380111.
15. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS; CKD Prognosis Consortium. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518-2531. doi: 10.1001/jama.2014.6634.
16. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest. 1999;59:1-8.
17. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD III, Zhang YL, Greene T, Levey AS. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51:395-406. doi: 10.1053/j.ajkd.2007.11.018.0
18. Padala S, Tighiouart H, Inker LA, Contreras G, Beck GJ, Lewis J, Steffes M, Rodby RA, Schmid CH, Levey AS. Accuracy of a GFR estimating equation over time in people with a wide range of kidney function. Am J Kidney Dis. 2012;60:217-224. doi: 10.1053/j.ajkd.2012.01.024.
19. Blackburn H. Classification of the electrocardiogram for population studies: Minnesota Code. J Electrocardiol. 1969;2:305-310.
20. Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, Satterfield S, Cummings SR, Newman AB, Fried LF. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2006;17:254-261. doi: 10.1681/ASN.2005050545.
21. Kalogeropoulos A, Georgiopoulou V, Psaty BM, Rodondi N, Smith AL, Harrison DG, Liu Y, Hoffmann U, Bauer DC, Newman AB, Kritchevsky SB, Harris TB, Butler J; Health ABC Study Investigators. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol. 2010;55:2129-2137. doi: 10.1016/j.jacc.2009.12.045.
22. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, Bauer DC, Satterfield S, Smith AL, Vaccarino V, Newman AB, Harris TB, Wilson PW, Kritchevsky SB; Health ABC Study. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail. 2008;1:125-133. doi: 10.1161/CIRCHEARTFAILURE.108.768457.
23. Patel KV, Longo DL, Ershler WB, Yu B, Semba RD, Ferrucci L, Guralnik JM. Haemoglobin concentration and the risk of death in older adults: differences by race/ethnicity in the NHANES III follow-up. Br J Haematol. 2009;145:514-523. doi: 10.1111/j.1365-2141.2009.07659.x.
24. Patel KV, Harris TB, Faulhaber M, Angleman SB, Connelly S, Bauer DC, Kuller LH, Newman AB, Guralnik JM. Racial variation in the relationship of anemia with mortality and mobility disability among older adults. Blood. 2007;109:4663-4670. doi: 10.1182/blood-2006-10-055384.
25. Bibbins-Domingo K, Pletcher MJ, Lin F, Vittinghoff E, Gardin JM, Arynchyn A, Lewis CE, Williams OD, Hulley SB. Racial differences in incident heart failure among young adults. N Engl J Med. 2009;360:1179-1190. doi: 10.1056/NEJMoa0807265.
26. Bahrami H, Kronmal R, Bluemke DA, Olson J, Shea S, Liu K, Burke GL, Lima JA. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008;168:2138-2145. doi: 10.1001/archinte.168.19.2138.
27. Guo L, Wang AH, Sun YL, Lv L, Xu CE. Serum erythropoietin level predicts the prognosis of chronic heart failure with or without anemia. Exp Ther Med. 2013;6:1327-1331. doi: 10.3892/etm.2013.1307.
28. van der Meer P, van Veldhuisen DJ, Januzzi JL. Erythropoietin in cardiovascular diseases: exploring new avenues. Clin Sci (Lond). 2008;114:289-291. doi: 10.1042/CS20070392.
29. Volpe M, Tritto C, Testa U, Rao MA, Martucci R, Mirante A, Enea I, Russo R, Rubattu S, Condorelli GL. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol. 1994;74:468-473.
30. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032. doi: 10.1056/NEJMoa0907845.
31. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590. doi: 10.1056/NEJM199808273390903.
32. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363:1146-1155. doi: 10.1056/NEJMoa1005109.
33. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791-798. doi: 10.1038/ki.2008.295.
34. McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, Califf RM. Cardiovascular toxicity of epoetinalfa in patients with chronic kidney disease. Am J Nephrol. 2013;37:549-558. doi: 10.1159/000351175.
35. Mukhopadhyay P, Sinha U, Banerjee J, Choudhury AR, Philips CA. The effects in correction of anaemia in chronic kidney disease with erythropoietin therapy-preference to cardiovascular, neurologic and general well-being of patients from a tertiary care centre. J Indian Med Assoc. 2012;110:885-888.
36. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med. 2008;264:405-432. doi: 10.1111/j.1365-2796.2008.02024.x.
37. Kleijn L, Westenbrink BD, van der Meer P. Erythropoietin and heart failure: the end of a promise Eur J Heart Fail. 2013;15:479-481. doi: 10.1093/eurjhf/hft058.
38. Tada H, Kagaya Y, Takeda M, Ohta J, Asaumi Y, Satoh K, Ito K, Karibe A, Shirato K, Minegishi N, Shimokawa H. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res. 2006;71:466-477. doi: 10.1016/j.cardiores.2006.05.010.
39. Santhanam AV, d'Uscio LV, Katusic ZS. Cardiovascular effects of erythropoietin an update. Adv Pharmacol. 2010;60:257-285. doi: 10.1016/B978-0-12-385061-4.00009-X.
40. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol. 2007;2:1274-1282. doi: 10.2215/CJN.02380607.
41. Belonje AM, Voors AA, van der Meer P, van Gilst WH, Jaarsma T, van Veldhuisen DJ. Endogenous erythropoietin and outcome in heart failure. Circulation. 2010;121:245-251. doi: 10.1161/CIRCULATIONAHA.108.844662.
42. Bárány P. Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant. 2001;16:224-227.
43. Tsitsika A, Stamoulakatou A, Kafritsa Y, Paleologos G, Panayotou I, Premetis E, Roma E, Papassotiriou I. Erythropoietin levels in children and adolescents with inflammatory bowel disease. J Pediatr Hematol Oncol. 2005;27:93-96.
44. Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, Caro J, Morris E. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol. 1992;2:1405-1416.